This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2025 Dec 4;393(22):2276.

doi: 10.1056/NEJMc2515117.

Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Tadasu Nagaoka¹

Affiliations

PMID: 41337725
DOI: 10.1056/NEJMc2515117

Comment

Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Tadasu Nagaoka. N Engl J Med. 2025.

. 2025 Dec 4;393(22):2276.

doi: 10.1056/NEJMc2515117.

Author

Tadasu Nagaoka¹

Affiliation

¹ Public Matto Ishikawa Central Hospital, Hakusan, Japan.

PMID: 41337725
DOI: 10.1056/NEJMc2515117

No abstract available

PubMed Disclaimer

Comment on

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fernández Landó L, Denning M, Ludwig L, Chen Y; ACHIEVE-1 Trial Investigators. Rosenstock J, et al. N Engl J Med. 2025 Sep 18;393(11):1065-1076. doi: 10.1056/NEJMoa2505669. Epub 2025 Jun 21. N Engl J Med. 2025. PMID: 40544435 Clinical Trial.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.